Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAMeLot-1 bleximenib first-in-human study in relapsed/refractory acute leukemia
jRCT2011240023Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of bleximenib in Acute Leukaemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events, Number of participants with adverse events by severity and 2 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
bleximenib
03
Conditions
Acute Leukaemiaacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2011240023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240023.